MNKD - MannKind Corp Stock Price, Fair Value and News

5.84USD+0.04 (+0.69%)Market Closed

Market Summary

USD5.84+0.04

Market Closed

0.69%

MNKD Stock Price

View Fullscreen

MNKD RSI Chart

MNKD Valuation

Market Cap

1.6B

Price/Earnings (Trailing)

187.38

Price/Sales (Trailing)

7.08

EV/EBITDA

46.44

Price/Free Cashflow

512.51

MNKD Price/Sales (Trailing)

MNKD Profitability

EBT Margin

4.59%

Return on Equity

-3.69%

Return on Assets

1.76%

Free Cashflow Yield

0.2%

MNKD Fundamentals

MNKD Revenue

Revenue (TTM)

224.6M

Rev. Growth (Yr)

63.1%

Rev. Growth (Qtr)

13.32%

MNKD Earnings

Earnings (TTM)

8.5M

Earnings Growth (Yr)

208.52%

Earnings Growth (Qtr)

658.74%

Breaking Down MNKD Revenue

Last 7 days

2.3%

Last 30 days

12.5%

Last 90 days

38.1%

Trailing 12 Months

32.1%

How does MNKD drawdown profile look like?

MNKD Financial Health

Current Ratio

3.84

MNKD Investor Care

Shares Dilution (1Y)

3.03%

Diluted EPS (TTM)

0.04

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	224.6M	0	0	0
2023	128.4M	158.1M	176.5M	199.0M
2022	70.0M	65.6M	76.2M	99.8M
2021	66.3M	74.5M	81.4M	75.4M
2020	61.8M	61.9M	62.7M	65.1M
2019	41.8M	53.0M	63.1M	63.0M
2018	12.2M	13.9M	16.4M	27.9M
2017	134.0M	93.3M	52.5M	11.7M
2016	0	0	131.1M	174.8M
2012	0	0	43.7M	87.4M
2011	82.3K	71.5K	60.8K	50.0K
2010	0	0	0	93.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DP Treprostinil, an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease, and idiopathic pulmonary and cystic fibrosis. In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

CEO	Dr. Michael E. Castagna Pharm.D.
WEBSITE	mannkindcorp.com
INDUSTRY	Biotechnology
EMPLOYEES	391

MannKind Corp Frequently Asked Questions

What is the ticker symbol for MannKind Corp? What does MNKD stand for in stocks?

MNKD is the stock ticker symbol of MannKind Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MannKind Corp (MNKD)?

As of Fri Jul 26 2024, market cap of MannKind Corp is 1.59 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MNKD stock?

You can check MNKD's fair value in chart for subscribers.

Is MannKind Corp a good stock to buy?

The fair value guage provides a quick view whether MNKD is over valued or under valued. Whether MannKind Corp is cheap or expensive depends on the assumptions which impact MannKind Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MNKD.

What is MannKind Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, MNKD's PE ratio (Price to Earnings) is 187.38 and Price to Sales (PS) ratio is 7.08. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MNKD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on MannKind Corp's stock?

In the past 10 years, MannKind Corp has provided -0.182 (multiply by 100 for percentage) rate of return.